0001437749-24-006301.txt : 20240301 0001437749-24-006301.hdr.sgml : 20240301 20240301163054 ACCESSION NUMBER: 0001437749-24-006301 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arch Therapeutics, Inc. CENTRAL INDEX KEY: 0001537561 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 460524102 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-54986 FILM NUMBER: 24710427 BUSINESS ADDRESS: STREET 1: 235 WALNUT STREET, SUITE 6 CITY: FRAMINGHAM STATE: MA ZIP: 01702 BUSINESS PHONE: 617-431-2313 MAIL ADDRESS: STREET 1: 235 WALNUT STREET, SUITE 6 CITY: FRAMINGHAM STATE: MA ZIP: 01702 FORMER COMPANY: FORMER CONFORMED NAME: ALMAH,INC DATE OF NAME CHANGE: 20111216 10-K/A 1 arch20230930_10ka.htm FORM 10-K/A arch20230930_10ka.htm
true 0001537561 0001537561 2022-10-01 2023-09-30 0001537561 2023-03-31 0001537561 2024-02-14 iso4217:USD xbrli:shares
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-K/A
(Amendment No. 1)
 
(Mark One)
 
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended September 30, 2023
--09-30FY2023
 
OR
 
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______________________to ______________________
 
Commission File Number: 000-54986
 
ARCH THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
  
46-0524102
(State or other jurisdiction of incorporation or organization)
  
(I.R.S. Employer Identification No.)
     
235 Walnut Street, Suite 6
    
Framingham, MA
  
01702
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code (617) 431-2313
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
N/A
N/A
N/A
 
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $0.001 per share
(Title of Class)
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
 
 
 
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer ☐
  
Accelerated filer ☐
Non-accelerated filer ☒
  
Smaller reporting company ☒
   
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act. ☐
 
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
 
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued statements. ☐
 
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to Section 240.10D-1(b). ☐
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes ☐ No ☒
 
The aggregate market value of the registrant’s voting and non-voting common equity held by non-affiliates as of the last business day of the registrant’s most recently completed second fiscal quarter, computed by reference to the average of the bid and asked price of such common equity, was approximately $4,000,000. For purposes of this calculation, it has been assumed that shares of common stock held by each director, each officer and each person who owns 10% or more of the registrant’s outstanding common stock are held by affiliates.
 
As of February 14, 2024, 4,742,363 shares of the registrant’s common stock were outstanding.
 
DOCUMENTS INCORPORATED BY REFERENCE
 
None.
 
Weinberg & Company, P.A.
Los Angeles, California
PCAOB ID 572
 
EXPLANATORY NOTE
 
Arch Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment”) to its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, which was originally filed with the Securities and Exchange Commission (“SEC”) on February 15, 2024 (the “Form 10-K”) solely to correct and replace the disclosure in connection with the beneficial ownership of shares and voting power held by certain shareholders, directors, and officers included in Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
 
Except for the items described above or contained in this Amendment, this Amendment continues to speak as of the date of the Form 10-K, and does not modify, amend or update any other item or disclosures in the Form 10-K, including the financial information. Accordingly, this Amendment should be read in conjunction with the Form 10-K and the Company’s other filings with the SEC.
 
 
 
 
PART III
 
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
 
Securities Authorized for Issuance under Equity Compensation Plans
 
On June 18, 2013, our Board and the holders of a majority of our standing common stock approved and adopted the Arch Therapeutics, Inc. 2013 Stock Incentive Plan (the “2013 Plan”). The Plan permits us to grant a variety of forms of awards, including stock options, stock appreciation rights, restricted stock, restricted stock units, and dividend equivalent rights, to allow us to adapt our incentive compensation program to meet our needs. As of September 30, 2023, the Plan has reserved 185,572 shares of our Common Stock for issuance thereunder in awards granted to employees, directors and/or consultants. The Plan provides that on the first business day of each fiscal year commencing with fiscal year 2013, the number of shares of our Common Stock reserved for issuance under the Plan for all awards except for incentive stock option awards will be subject to increase by an amount equal to the lesser of (i) 15,000 shares, (ii) 4% of the number of shares outstanding on the last day of our immediately preceding fiscal year, or (iii) such lesser number of shares as determined by the administrator of the Plan, which is currently our Board of Directors. On June 18, 2023, the 2013 stock Incentive Plan expired.
 
On July 18, 2023, our Board adopted and approved the 2023 Equity Incentive Plan (the “2023 Plan”) and reserved 455,169 shares of the Company’s common stock, par value $0.001 for issuance thereunder to employees, officers, directors and consultants of the Company. The Plan has a term of 6 years and is intended to replace the Company’s 2013 Stock Incentive Plan, which expired on June 18, 2023. The Plan permits the Company to grant a variety of forms of awards, including stock options, stock appreciation rights, restricted stock, restricted stock units, and dividend equivalent rights, to allow the Company to adapt its incentive compensation program to meet its needs. In addition, the number of shares of Common Stock available for issuance under the Plan will automatically increase on October 1st of each fiscal year of the Company commencing with October 1, 2023, and on each October 1 thereafter until the 10th anniversary of the date of the Plan’s initial adoption by the Board, in an amount equal to six percent (6%) of the total number of shares of Common Stock outstanding on September 30th of the preceding fiscal year. Furthermore, effective at the close of business on the date of the closing (the “Uplist Date”) of the public offering in connection with which the Common Stock becomes tradeable on a national exchange and on the first day of each fiscal quarter of the Company thereafter until the earlier of (i) the five-year anniversary of the Uplist Date and (ii) August 30, 2028, the number of shares of Common Stock available for issuance under the Plan shall automatically increase by an amount equal to fifteen percent (15%) of the incremental number of shares of Common Stock, if any, issued by the Company (i) with respect to the Uplist Date, since the date on which the stockholders ratified the Plan, and (ii) with respect to each fiscal quarter thereafter, during the previous fiscal quarter (excluding in each case shares of Common Stock issued pursuant to awards under the Plan).
 
 
 
 
The following table provides information as of September 30, 2023 with respect to our equity compensation plan:
 
Equity Compensation Plan Information
 
                   
Number of
  
                   
securities
  
                   
remaining
  
   
Number of
            
available for
  
   
securities to
            
future
  
   
be issued
            
issuance
  
   
upon
    
Weighted-
    
under
  
   
exercise
    
average
    
equity
  
   
Of
    
exercise
    
compensation
  
   
outstanding
    
price of
    
plans
  
   
options,
    
outstanding
    
(excluding
  
   
warrants
    
options,
    
securities
  
   
And
    
warrants
    
reflected in
  
   
rights
    
and rights
    
column (a))
  
Plan category
  
(a)
    
(b)
    
(c)
 
Equity compensation plans approved by security holders
                        
2013 Stock Incentive Plan
     100,300     $ 38.00       -  
2023 Stock Incentive Plan
     -       -       455,169  
Equity compensation plans not approved by security holders
     -       -       -  
Total
     100,300     $ 38.00       455,169  
 
Security Ownership of Certain Beneficial Owners and Management
 
The following table sets forth certain information regarding the beneficial ownership of our Common Stock by (i) each person who, to our knowledge, beneficially owns more than 5% of our Common Stock; (ii) each of our directors and named executive officers; and (iii) all of our directors and executive officers as a group. Unless otherwise indicated in the footnotes to the following table, the address of each person named in the table is: c/o Arch Therapeutics, Inc., 235 Walnut St., Suite #6, Framingham, Massachusetts 01702. The information set forth in the table below is based on 4,742,363 shares of our Common Stock outstanding on February 1, 2024. Shares of our Common Stock subject to options, warrants, or other rights currently exercisable or exercisable within 60 days of February 1, 2024 are deemed to be beneficially owned and outstanding for computing the share ownership and percentage of the person holding such options, warrants or other rights, but are not deemed outstanding for computing the percentage of any other person.
 
The following table is presented after taking into account the applicable ownership limitation to which certain holders of our Series Convertible Notes, and all the holders of our Pre-Funded Warrants, Common Warrants, 2022 Warrants, 2022 Placement Agent Warrants, 2022 Notes, Subordinated Notes, Series I Warrants, 2019 Placement Agent Warrants, Series K Warrants and 2022 Placement Agent Warrants are subject to the applicable ownership limitations. In general, the ownership limitation prevents holders from exercising the warrant to the extent such exercise would result in the holder owning more shares than a certain ownership percentage, which is initially set below 5%, and such ownership limitation may be waived at the holder’s discretion, provided that such waiver will not become effective until the 61st day after delivery of such waiver notice.
 
 
 
 
Name of Beneficial Owner
  
Number of
Shares
Beneficially
Owned
    
Percentage
of
Shares
Beneficially
Owned
(1)
  
5%+ Stockholders:
                
                 
Oasis Capital, LLC (2)
     473,762       9.9 %
                 
Bigger Capital Fund, LP & District 2 Capital Fund LP (3)
     300,000       6.3 %
                 
Walleye Opportunities Master Fund 1 Ltd (4)
     473,762       9.9 %
                 
Cavalry Fund 1 LP (5)
     300,000       6.3 %
                 
Brandt & Mona Wilson (6)
     473,762       9.9 %
                 
Ana and Michael A. Parker (7)
     473,762       9.9 %
                 
Andrew Stahl (8)
     473,762       9.9 %
                 
Sixth Borough Capital Fund, LP (9)
     473,762       9.9 %
                 
Named Executive Officers and Directors:
                
                 
Terrence Norchi (10)
     128,308       2.47 %
                 
Punit Dhillon (11)
     6,042       *  
                 
Laurence Hicks (12)
     42,660       1.0 %
                 
Michael Abrams (13)
     44,800       1.0 %
                 
Daniel Yrigoyen (14)
     3,403       *  
                 
Guy Fish (15)
     2,187       *  
                 
Named Officers and Directors as a Group
     227,400       4.8 %
 
* Less than one percent.
 
Shares of our Common Stock subject to options, warrants, or other rights currently exercisable or convertible or exercisable or convertible within 60 days of February 1, 2024, are deemed to be beneficially owned and outstanding for computing the share ownership and percentage of the person holding such options, warrants or other rights, but are not deemed outstanding for computing the percentage of any other person.
 
(1)
Except as otherwise indicated, we believe that each of the beneficial owners of the Common Stock listed previously, based on information furnished by such owners, has sole investment and voting power with respect to the shares listed as beneficially owned by such owner, subject to community property laws where applicable. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities.
 
(2)
Represents 300,000 shares of Common Stock owned by Oasis Capital, LLC. Gives effect to (a) 131,292 shares of Common Stock issuable upon conversion of the First Notes (the “First Conversion Shares”); (b) 120,725 First Warrants; (c) 27,353 shares of Common Stock issuable upon conversion of the Second Notes (the “Second Conversion Shares”); (d) 50,302 Second Warrants; (e) 76,886 shares of Common Stock issuable upon conversion of the Third Notes (the “Third Conversion Shares”); (f) 141,396 Third Warrants; (g) 1,005,251 Pre-Funded Warrants; and (h) 2,552,766 Common Warrants, all of which are subject to conversion or exercise restrictions that prohibit conversion or exercise until such time as the holder would not beneficially own, after such conversion or exercise, more than 4.99% or 9.99% (as the case may be) of the outstanding shares of Common Stock; provided, however, that the holder may waive such ownership limitation, in which case any waiver would become effective sixty-one (61) days after the holder’s delivery of such waiver notice. As of February 14, 2024, Oasis Capital, LLC has not waived such limitation.  
 
 
 
 
(3)
Represents 300,000 shares of Common Stock owned by, and split evenly between, Bigger Capital Fund, LP and District 2 Capital Fund LP with a common control person. Gives effect to (a) 131,292 First Conversion Shares; (b) 120,726 First Warrants; (c) 27,354 Second Conversion Shares; (d) 50,302 Second Warrants; (e) 989,459 Pre-Funded Warrants; and (f) 2,552,652 Common Warrants held in the aggregate by Bigger Capital Fund, LP and District 2 Capital Fund LP, all of which are subject to conversion or exercise restrictions that prohibit conversion or exercise until such time as the holder would not beneficially own, after such conversion or exercise, more than 4.99% or 9.99% (as the case may be) of the outstanding shares of Common Stock; provided, however, that the holder may waive such ownership limitation, in which case any waiver would become effective sixty-one (61) days after the holder’s delivery of such waiver notice. As of February 14, 2024, neither Bigger Capital Fund, LP, nor District 2 Capital Fund LP has waived such limitation.  
 
(4)
Represents 300,000 shares of Common Stock owned by Walleye Opportunities Master Fund Ltd. Gives effect to (a) 976,278 Pre-Funded Warrants; and (b) 2,552,556 Common Warrants, all of which are subject to exercise restrictions that prohibit exercise until such time as the holder would not beneficially own, after such exercise, more than 4.99% or 9.99% (as the case may be) of the outstanding shares of Common Stock; provided, however, that the holder may waive such ownership limitation, in which case any waiver would become effective sixty-one (61) days after the holder’s delivery of such waiver notice. As of February 14, 2024, Walleye Opportunities Master Fund Ltd has not waived such limitation.
 
(5)
Represents 300,000 shares of Common Stock owned by Cavalry Fund I LP. Gives effect to (a) 52,517 First Conversion Shares; (b) 48,290 First Warrants; (c) 10,941 Second Conversion Shares; (d) 20,121 Second Warrants; (e) 985,064 Pre-Funded Warrants; and (f) 2,552,620 Common Warrants, all of which are subject to conversion or exercise restrictions that prohibit conversion or exercise until such time as the holder would not beneficially own, after such conversion or exercise, more than 4.99% or 9.99% (as the case may be) of the outstanding shares of Common Stock; provided, however, that the holder may waive such ownership limitation, in which case any waiver would become effective sixty-one (61) days after the holder’s delivery of such waiver notice. As of February 14, 2024, Cavalry Fund I LP has not waived such limitation.  
 
(6)
Represents 300,000 shares of Common Stock owned individually by Brandt and Mona Wilson. Gives effect to (a) 976,278 Pre-Funded Warrants; and (b) 2,552,556 Common Warrants, all of which are subject to exercise restrictions that prohibit exercise until such time as the holder would not beneficially own, after such exercise, more than 4.99% or 9.99% (as the case may be) of the outstanding shares of Common Stock; provided, however, that the holder may waive such ownership limitation, in which case any waiver would become effective sixty-one (61) days after the holder’s delivery of such waiver notice. As of February 14, 2024, neither Brandt Wilson nor Mona Wilson had waived such limitation.  
 
(7)
Represents (i) 235,448 shares of Common Stock owned individually by Ana Parker, Michael A. Parker’s spouse; (ii) 38,056 shares of Common Stock owned individually by Mr. Parker; (iii) 25,000 shares of Common Stock owned through Tungsten, of which Mr. Parker is the sole manager and (iv) 1,500 shares of restricted stock granted to Mr. Parker on September 27, 2021. Gives effect to (a) 82,465 Pre-Funded Warrants; (b) 549,486 Common Warrants; (c) 103,559 First Conversion Shares; (d) 48,290 First Warrant Shares; (e) any of the 17.144 shares of Common Stock that may be acquired upon the exercise of Series I Warrants (which expire October 18, 2024); or (f) any of the 23,440 shares that may be acquired upon the exercise of Series K Warrants (which expire on August 11, 2026), since such warrants cannot be exercised until such time as the holder would not beneficially own, after such exercise, more than 4.99% or 9.99% (as the case may be) of the outstanding shares of Common Stock; provided, however, that the holder may waive such ownership limitation, in which case such waiver will become effective sixty-one (61) days after the holder’s delivery of such waiver notice. As of February 14, 2024, neither Ms. Parker nor Mr. Parker have waived such limitation. 
 
(8)
Represents 300,000 shares of Common Stock owned individually by Andrew Stahl. Gives effect to (a) 976,278 Pre-Funded Warrants; and (b) 2,552,556 Common Warrants, all of which are subject to exercise restrictions that prohibit exercise until such time as the holder would not beneficially own, after such exercise, more than 4.99% or 9.99% (as the case may be) of the outstanding shares of Common Stock; provided, however, that the holder may waive such ownership limitation, in which case any waiver would become effective sixty-one (61) days after the holder’s delivery of such waiver notice. As of February 14, 2024, Mr. Stahl had not waived such limitation.
 
 
 
 
(9)
Represents 300,000 shares of Common Stock owned by Sixth Borough Capital Fund, LP. Gives effect to (a) 63,869 Pre-Funded Warrants; and (b) 727,738 Common Warrants, all of which are subject to exercise restrictions that prohibit exercise until such time as the holder would not beneficially own, after such exercise, more than 4.99% or 9.99% (as the case may be) of the outstanding shares of Common Stock; provided, however, that the holder may waive such ownership limitation, in which case any waiver would become effective sixty-one (61) days after the holder’s delivery of such waiver notice. As of February 14, 2024, Sixth Borough Capital Fund, LP has not waived such limitation.
 
(10)
Represents (a) 50,000 shares of Common Stock held by Twelve Pins Partners, LLC, with respect to which Dr. Norchi is the sole member and holds sole voting and investment control; (b) 7,098 shares issued to Dr. Norchi upon the closing of the Merger in exchange for the cancellation of shares of Common Stock and convertible notes of ABS owned by him immediately prior to the closing of the Merger; (c) 5,650 shares of restricted stock granted to Dr. Norchi on May 3, 2016; (d) 3,250 shares of restricted stock granted to Dr. Norchi on February 3, 2017; (e) 1,800 shares of restricted stock granted to Dr. Norchi on July 19, 2018; (f) 2,626 First Conversion Shares; (g) 2,415 First Warrants; and (h) 363 First Inducement Shares; (i) 34,520 shares subject to options exercisable within 60 days after February 1, 2024; (j) 6,862 shares of common stock purchased, 13,724 Common Warrants. Dr. Norchi disclaims beneficial ownership of the securities held by Twelve Pins Partners, LLC except to the extent of his pecuniary interest therein.
 
(11)
Represents 6,042 shares of Common Stock subject to options exercisable within 60 days after February 1, 2024.
 
(12)
Represents 3,542 shares of Common Stock subject to options exercisable within 60 days after February 1, 2024. Includes (i) 137 shares of Common Stock, (ii) 3,939 First Conversion Shares, (iii) 3,622 First Warrant Shares, (iv) 544 First Inducement Shares; (v) 10,292 shares of common stock held by Drake Partners Equity LLC, in which Mr. Hicks has an ownership interest, and (vi) 20,584 Common Warrants held by Drake Partners Equity LLC, in which Mr. Hicks has an ownership interest.
 
(13)
Represents (i) 3,939 First Conversion Shares; (ii) 3,622 First Warrant Shares; (iii) 544 First Inducement Shares; (iv) 10,292 shares of common stock purchased, (v) 5,819 shares of Common Stock subject to options exercisable within 60 days after February 1, 2024, and (vi) 20,584 Common Warrants.
 
 
(14)
Represents 750 shares of restricted stock granted to Mr. Yrigoyen on July 30, 2021, and 2,653 shares of Common Stock subject to options exercisable within 60 days after February 1, 2024.
 
 
(15)
Represents 2,187 shares of Common Stock subject to options exercisable within 60 days after February 1, 2024.
 
 
 
 
PART IV
 
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
 
(b) Exhibits
 
         
Incorporated By Reference
Exhibit
No.
  
Exhibit Title
  
Filed
Herewith
Form
  
Exhibit
No.
  
File No.
  
Filing Date
                       
31.1
   X
       
31.2
   X
 
101.INS
  
Inline XBRL Instance Document
X
       
101.SCH
  
Inline XBRL Taxonomy Extension Schema Document
X
       
101.CAL
  
Inline XBRL Taxonomy Extension Calculation Linkbase Document
X
       
101.DEF
  
Inline XBRL Taxonomy Extension Definition Linkbase Document
X
       
101.LAB
  
Inline XBRL Taxonomy Extension Label Linkbase Document
X
​
  
​
​
101.PRE
  
Inline XBRL Taxonomy Extension Presentation Linkbase Document
X
​
  
​
​
104
  
Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101)
X
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
   
Arch Therapeutics, Inc.
 
By:
/s/ Terrence W. Norchi, MD
Date: March 1, 2024
  
Terrence W. Norchi, MD
   
President and Chief Executive Officer
 
 
 EX-31.1 2 ex_631800.htm EXHIBIT 31.1 ex_631800.htm

Exhibit 31.1

 

 

CERTIFICATIONS

 

I, Terrence W. Norchi, certify that:

 

 

1.

I have reviewed this Annual Report on Form 10-K/A of Arch Therapeutics, Inc.;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d- 15(f)) for the registrant and have:

 

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

1.

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

2.

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

March 1, 2024

 

/s/ Terrence W. Norchi, MD
Terrence W. Norchi, MD
President and Chief Executive Officer (Principal Executive Officer)

 

 
 EX-31.2 3 ex_631801.htm EXHIBIT 31.2 ex_631801.htm

Exhibit 31.2

 

 

CERTIFICATIONS

 

I, Michael S. Abrams, certify that:

 

 

1.

I have reviewed this Annual Report on Form 10-K/A of Arch Therapeutics, Inc.

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d- 15(f)) for the registrant and have:

 

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

1.

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

2.

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

March 1, 2024

 

/s/ Michael S. Abrams
Michael S. Abrams
Chief Financial Officer and Treasurer (Principal Financial Officer)

 
 EX-101.SCH 4 arch-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 5 arch-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 arch-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Annual Report Document, Period End Date Current Fiscal Year End Date Document, Fiscal Period Focus Document, Fiscal Year Focus Document, Transition Report Entity, File Number Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Title of 12(g) Security Entity, Well-known Seasoned Issuer Entity, Voluntary Filers Entity, Current Reporting Status Entity, Interactive Data, Current Entity, Filer Category Entity, Small Business Entity, Emerging Growth Company ICFR Auditor Attestation Flag Document, Financial Statement Error Correction Flag Entity, Shell Company Entity, Public Float Entity, Common Stock Shares, Outstanding Auditor Name Auditor Location Auditor Firm ID Amendment Description Amendment Flag Entity, Central Index Key EX-101.PRE 7 arch-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information - USD ($)
 12 Months Ended
Sep. 30, 2023
Feb. 14, 2024
Mar. 31, 2023
Document Information [Line Items]      
Entity, Registrant Name ARCH THERAPEUTICS, INC.    
Document, Type 10-K/A    
Document, Annual Report true    
Document, Period End Date Sep. 30, 2023    
Current Fiscal Year End Date --09-30    
Document, Fiscal Period Focus FY    
Document, Fiscal Year Focus 2023    
Document, Transition Report false    
Entity, File Number 000-54986    
Entity, Incorporation, State or Country Code NV    
Entity, Tax Identification Number 46-0524102    
Entity, Address, Address Line One 235 Walnut Street, Suite 6    
Entity, Address, City or Town Framingham    
Entity, Address, State or Province MA    
Entity, Address, Postal Zip Code 01702    
City Area Code 617    
Local Phone Number 431-2313    
Title of 12(g) Security Common Stock, par value $0.001 per share    
Entity, Well-known Seasoned Issuer No    
Entity, Voluntary Filers No    
Entity, Current Reporting Status Yes    
Entity, Interactive Data, Current Yes    
Entity, Filer Category Non-accelerated Filer    
Entity, Small Business true    
Entity, Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document, Financial Statement Error Correction Flag false    
Entity, Shell Company false    
Entity, Public Float     $ 4,000,000
Entity, Common Stock Shares, Outstanding   4,742,363  
Auditor Name Weinberg & Company, P.A.    
Auditor Location Los Angeles, California    
Auditor Firm ID 572    
Amendment Description Arch Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment”) to its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, which was originally filed with the Securities and Exchange Commission (“SEC”) on February 15, 2024 (the “Form 10-K”) solely to correct and replace the disclosure in connection with the beneficial ownership of shares and voting power held by certain shareholders, directors, and officers included in Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.   Except for the items described above or contained in this Amendment, this Amendment continues to speak as of the date of the Form 10-K, and does not modify, amend or update any other item or disclosures in the Form 10-K, including the financial information. Accordingly, this Amendment should be read in conjunction with the Form 10-K and the Company’s other filings with the SEC.    
Amendment Flag true    
Entity, Central Index Key 0001537561    
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( -F#85@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #9@V%8G9TKT>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$G*&";UI:.G#@8K;.QF;+4UBV-C:R1]^R5>FS*V!]C1TN]/ MGT"M#D+[B,_1!XQD,=V-KNN3T&'-3D1! "1]0J=2.27ZJ7GPT2F:GO$(0>D/ M=42H.;\'AZ2,(@4SL @+D^"V@68J[^BE7PIN#5OJY$P\7JX7UV_>%W$W;>V(/] MQ\970=G"K[N07U!+ P04 " #9@V%8F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M -F#85A>?QM!> D "8U 8 >&PO=V]R:W-H965T&UL MM9M=;]LX%H;O^RL(SZ!H@<36AYVD;1+ =9*M,6T:Q&F+[F(O:(FVN)5$+4G% MS;^?0\J6K):B[0'3B\8?.J_(1X?4>6GJ?,7X#Y$0(M'/+,W%12^1LG@[&(@H M(1D6?5:0'+Y9,)YA"6_YR2##-.]=GNO/[OCE.2ME2G-R MQY$HLPSSI_8RNDZ*/0.T*!%X2&!DWLX3=DWD?^4(%7]O!/F,/9?=/96[T):_2AU@MWH=_F_9^/S@"#\D?0N7_[AGWCO3+A^+?H;; J3!._?:X@YDY4FLS"QIFP5Z% MV U-";HMLSGA1E9V%<_SCD?#-VTSQB'#)+ MFX C-),P\2/&T825N>1/\#[4FL3;"I_?[_2_P'_1-,8 MABM=T*CR4I;\LVL.3XZ]43#TO<"(SVGE[TJMC:^I_7U[\;[!-XYCD!?U"Z1] MZ.?B M7?23T9?:@P[F]AS.P6^L@V^O]G_C=L>$A +OW[3HOFW8)3W_M&/J<^H?7*FU MP34.PK?7_'IHCCG!W9CL B?^J1&24]O@2JV]X-KXAL!>Z7]DVEPE++?5W_-\5!".1(*YT5'8I0]&^AR.(F@<1;"?H_A& MTO3X1PZW4<"*!>1CC*9"E!T):1>]949N3IV%*[4VM\99!/LYBZ\L!0N!P4,H M3\:-;G^'5 P[W$#3N(=C//4QS27CU$ZY:L\0U2",WNV87-ZDF@" M=>Z2E\*^%Z8 MQZA=J.OG&'O8P;2>PR $C4$(]C,(UQGA2S6E_0LD9 )5;U;@W)QU=L7.M4Q[ MW,'-"QE 1LE5Y7NDGQTDC-KM=-S:EA<*76 MWM/0&(9P_Q\:=^ATTW+J%%RIM6DU3B'X^70T__.Q\\FNAL;3;:SP]L&TM(++"0X@A]+B5,;GD,=P[CBJUD^T^G@Z#\"2L^[B&\1R>(&P\0;AC+]!ZZN_:2;0C_!NA^1SNN.@E MSHIWF]$+Z=D?&_<3V>4.3J3G, 9A8PQ">Q&_8:>6C]0\;^1GE_C(!!KG2RAM MU3(Z3NF"\9QB(SJGWL"56AM=XPU">TF_07=#>8:F5T9R=H71J7'QUAYU,*7G ML !A8P%">^4^AG(BUB7%%1$1IT5GEOV#XGO,HP0])."I"E)*&@G] VT?O9() M02__. L"[]UZ/.MW_KO7B JTH*DJKV4"KYOVW;(^\E4H?+J.K;^LHR5#5(KV M[C*DRB,&2: VV"'(?J1.OZBV;SRI[1M$[:M%,U) =0533;TU]@BM$@I=6&&! M&*=0](-/>E+M@\-7%&I_I;1>G:1$(*PV__Z,$@SC3=\AJ- ;NU^M&SR[GM1- M5:TB[G/AI'D"'JH/3IMYZ(A)7JFA*D'G!8Y\G_ROR71&F&C.J&^F1K MJ/JG[\2ZU=5H%5OCX7H"U\(X&Z"=WLLNT+5H8@\[ MF-)SF/^P,?^AW:S7Y3* XI"E4YAJ?Z*_B-E^V;6@>O='X>GHQ#=B<^K^7:E5 MV 9;#Y:HU2/]@(Z <5?FLGK&I/ZT?@AHK!]]&32'5T\0?<)J\4F@E"P@U.N? M0I7%JX=RJC>2%?HQE3F3DF7Z90+CG'!U 'R_8$QNWJ@3U(]&7?X-4$L#!!0 M ( -F#85BR]\)O[@( (D. - >&POL/0="LUK0BS5M94V&00JJ*:#-4 M9=#4BI*\ :>*![/)) HJPH2?)J*M+BO=>"O9"KWPIZ/)L\WGW!BC=[YGPV4R MIPO_[O3U]U;JBU>>;4_>G)Q,[LXNCNVG/7#F!VD2#$1I4DBQXPM]:S"LI*+> M/>$+/R.<+14#KX)4C&^L>0:&E>12>=HLE()88VD>+#RU(\C!$*=B0JJ>VS+8 MW^4P_0C8CD @XWP4./.M(4UJHC55XM(,^LF]\1'D#?W;36T4EHILIK/W_LZA M;PS)4JJC'4"CT M6M&"=?VX*T9^+/H4CT[JFF\^6BCT8-JB4E3%0Y7OW M5&FVVK?\4*2^I9W>5E-7X)IG_Z#F/YOGD@JJ"-\7;4K_)6?YV8J' _5O:.Y/ ME6/%3I'A^8O4& S'T-Y9=W#2C58/;I2%_Q7N+;XC]98MXYJ)8;1F>4[%HP// MA-=D:>[9@_AF?DX+TG)].X(+?]>_HCEKJWB<=0V)&&;M^E]@>=-HO,X,%Q,Y M[6B>#4-5+ONN9SJ&=7C X1BY[!\W@OE8S(T AO%@"C ?ZX7Q_$_KF:/KL1BF M;>Y$YJC/'/6Q7BXDZS\8C]LG-H][I7$& \ MP/1[N<9W&Z^0I^L V].G*@1;*5Z)V$KQ7 /BSAMXQ+%[MS$>\,!V :L=X'?S M0$VY?<(0=A73AKW!.!+'& *UZ*[1*$*R$\''O3_86Q*&<>Q& ',K"$,,@;<1 M1S %H %#PK"_!X_NHV![3P6[/Y_I3U!+ P04 " #9@V%8EXJ[', 3 M @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/ MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%" MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0 MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( -F#85@Z MJJ+G0 $ #P" / >&PO=V]R:V)O;VLN>&ULC5%=:\,P#/PKQC]@20SH\0RVT+E6J:'3"T4\4V#C M-E4DYPH]&09;B(S5'WC3B?PT9>H1-N6'$2&%GN5"6&-,W&_T_$8T'D&6A^[ M](2.(2X-PW.D0XMAU]&(B^S"1I_#6(<0Y_$_,5)=8P5+J@X> @\Y1G"=P) : M;)-6P7@H]+BB[H-5CX$E)+4* Y7L=D[E],H.KEGD7F08YRB#N+*#\%&MA1H# MV#:;7-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$% @ MV8-A6"0>FZ*M ^ $ !H !X;"]?+7_O MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I! MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6 MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 M ( -F#85AED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V3 M34[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\ MSYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#! M$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY M<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4Z MJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C M2&2FKW@ALO7L^T%.6X.^DX K @ $0 @ &O 9&]C4')O<',O8V]R92YX;6Q0 M2P$"% ,4 " #9@V%8F5R<(Q & "<)P $P @ ', 0 M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( -F#85A>?QM!> D "8U M 8 " @0T( !X;"]W;W)K&PO&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #9@V%899!YDAD! M #/ P $P @ $/& 6T-O;G1E;G1?5'EP97-=+GAM;%!+ 4!08 "0 ) #X" !9&0 ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 3 36 1 false 0 0 false 2 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.arch.com/20230930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports arch-20230930.xsd arch-20230930_def.xml arch-20230930_lab.xml arch-20230930_pre.xml arch20230930_10ka.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "arch20230930_10ka.htm": { "nsprefix": "arch", "nsuri": "http://www.arch.com/20230930", "dts": { "schema": { "local": [ "arch-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "arch-20230930_def.xml" ] }, "labelLink": { "local": [ "arch-20230930_lab.xml" ] }, "presentationLink": { "local": [ "arch-20230930_pre.xml" ] }, "inline": { "local": [ "arch20230930_10ka.htm" ] } }, "keyStandard": 36, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 0, "elementCount": 40, "unitCount": 2, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 36 }, "report": { "R1": { "role": "http://www.arch.com/20230930/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d202410KA", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230930_10ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d202410KA", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230930_10ka.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r2", "r3", "r4" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r2", "r3", "r4" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r2", "r3", "r4" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r2", "r3", "r4" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Financial Statement Error Correction Flag", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r2", "r3", "r4", "r6" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r0" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Common Stock Shares, Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r0" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r0" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Interactive Data, Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r7" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r0" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r0" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r0" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r0" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r8" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r2", "r3", "r4" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://www.arch.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" } } } ZIP 17 0001437749-24-006301-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-006301-xbrl.zip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end XML 18 arch20230930_10ka_htm.xml IDEA: XBRL DOCUMENT 0001537561 2022-10-01 2023-09-30 0001537561 2023-03-31 0001537561 2024-02-14 iso4217:USD shares true 0001537561 10-K/A true 2023-09-30 --09-30 FY 2023 false 000-54986 ARCH THERAPEUTICS, INC. NV 46-0524102 235 Walnut Street, Suite 6 Framingham MA 01702 617 431-2313 Common Stock, par value $0.001 per share No No Yes Yes Non-accelerated Filer true false false false false 4000000 4742363 Weinberg & Company, P.A. Los Angeles, California 572 Arch Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment”) to its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, which was originally filed with the Securities and Exchange Commission (“SEC”) on February 15, 2024 (the “Form 10-K”) solely to correct and replace the disclosure in connection with the beneficial ownership of shares and voting power held by certain shareholders, directors, and officers included in Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.   Except for the items described above or contained in this Amendment, this Amendment continues to speak as of the date of the Form 10-K, and does not modify, amend or update any other item or disclosures in the Form 10-K, including the financial information. Accordingly, this Amendment should be read in conjunction with the Form 10-K and the Company’s other filings with the SEC.